{"disease":{"id":"high-risk-of-stroke","name":"high risk of stroke"},"drugs":{"marketed":[{"drug_id":"no-oac","indication_name":"Atrial Fibrillation or Flutter with a High Risk of Stroke","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"No OAC","generic_name":"no-oac","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Factor Xa","drug_class":"Direct Oral Anticoagulant","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"no-oac","indication_name":"Atrial Fibrillation or Flutter with a High Risk of Stroke and at Least One Risk Factor for Stroke","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"No OAC","generic_name":"no-oac","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Factor Xa","drug_class":"Direct Oral Anticoagulant","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"no-oac","indication_name":"Atrial Fibrillation or Flutter with a High Risk of Stroke and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"No OAC","generic_name":"no-oac","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Factor Xa","drug_class":"Direct Oral Anticoagulant","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"no-oac","indication_name":"Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"No OAC","generic_name":"no-oac","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Factor Xa","drug_class":"Direct Oral Anticoagulant","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"no-oac","indication_name":"Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"No OAC","generic_name":"no-oac","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Factor Xa","drug_class":"Direct Oral Anticoagulant","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"no-oac","indication_name":"Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"No OAC","generic_name":"no-oac","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Factor Xa","drug_class":"Direct Oral Anticoagulant","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"no-oac","indication_name":"Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"No OAC","generic_name":"no-oac","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Factor Xa","drug_class":"Direct Oral Anticoagulant","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"no-oac","indication_name":"Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"No OAC","generic_name":"no-oac","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Factor Xa","drug_class":"Direct Oral Anticoagulant","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"no-oac","indication_name":"Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"No OAC","generic_name":"no-oac","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Factor Xa","drug_class":"Direct Oral Anticoagulant","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"no-oac","indication_name":"Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"No OAC","generic_name":"no-oac","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Factor Xa","drug_class":"Direct Oral Anticoagulant","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"no-oac","indication_name":"Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"No OAC","generic_name":"no-oac","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Factor Xa","drug_class":"Direct Oral Anticoagulant","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"no-oac","indication_name":"Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"No OAC","generic_name":"no-oac","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Factor Xa","drug_class":"Direct Oral Anticoagulant","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"no-oac","indication_name":"Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"No OAC","generic_name":"no-oac","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Factor Xa","drug_class":"Direct Oral Anticoagulant","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"no-oac","indication_name":"Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"No OAC","generic_name":"no-oac","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Factor Xa","drug_class":"Direct Oral Anticoagulant","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"no-oac","indication_name":"Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"No OAC","generic_name":"no-oac","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Factor Xa","drug_class":"Direct Oral Anticoagulant","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"no-oac","indication_name":"Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"No OAC","generic_name":"no-oac","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Factor Xa","drug_class":"Direct Oral Anticoagulant","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"no-oac","indication_name":"Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"No OAC","generic_name":"no-oac","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Factor Xa","drug_class":"Direct Oral Anticoagulant","quality_score":45,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":17,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05355948","title":"A Clinical Trial to Evaluate the Detection of Atrial Fibrillation for an One Day Versus More Than or Equal to Eight Days Using MEMO Patch PLUS in Individuals Aged ≥ 75 Years, or Those at High Risk of Stroke","phase":"NA","overall_status":"COMPLETED","enrollment_count":1000,"lead_sponsor_name":"Yonsei University","has_results":false},{"nct_id":"NCT07396493","title":"A Prospective, Single-arm Study Evaluating the Endothelialization Effect and Timeline of AnchorMan® Left Atrial Appendage Occluder in Non-valvular Atrial Fibrillation Patients at High Risk of Stroke","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":306,"lead_sponsor_name":"Shanghai Zhongshan Hospital","has_results":false},{"nct_id":"NCT06098235","title":"Oriental Intervention for Enhanced Neurocognitive Health (Orient) Diet in Populations With High Risk of Stroke (ENDS)","phase":"NA","overall_status":"RECRUITING","enrollment_count":160,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}